Research Thinking

Aging is not a recognized disease indication. That means longevity therapeutics must attach to specific age-related conditions for regulatory approval. We map the emerging consensus on indication selection for healthspan-extending mRNA drugs.

Protein structure prediction has transformed target validation workflows. We describe which computational tools we use to evaluate whether a longevity-associated protein is a tractable mRNA upregulation target — and where these tools still fall short.

Non-human primate studies are the gatekeeper between promising in vitro data and credible IND-enabling work. We share observations from our initial CNS biodistribution study — what crossed the BBB and what did not.

The hypothesis: genetic variants conserved across multiple long-lived species are less likely to cause harm and more likely to extend healthspan when upregulated.

iPSC-derived neurons have become the standard for early CNS toxicity and efficacy screening. We compare the tradeoffs with primary rodent culture.

Asset-in-licensing and research collaborations look different in 2025. We describe what data packages and target validation milestones matter most.

Senescent cells accumulate with age and drive chronic inflammation. We examine whether mRNA sequences can be designed to clear or reprogram senescent populations.

5-prime and 3-prime untranslated regions govern how long an mRNA survives in a cell. We explain why UTR optimization is as important as the coding sequence itself.

Between Weizmann, Hebrew University, and a decade of bioinformatics spinouts, Israel punches well above its size in computational life sciences.

Cryo-EM access, dynamic light scattering, and in vitro transfection assays — practical notes on what early-stage characterization looks like with limited resources.

Two proteins appear repeatedly in long-lived human populations and animal models of extended healthspan. We explain the biology and why they are credible mRNA intervention points.

From the clinical progress of ASO therapies to the first CNS-targeted mRNA programs entering IND, we survey the neurodegeneration pipeline.

Upregulating a longevity protein sounds straightforward. In practice, off-target effects and cellular stress responses make sequence selection non-trivial.

Blood-brain barrier crossing is one of the hardest delivery challenges in neurodegeneration therapeutics. We walk through what makes LNP design for CNS targets different.

Naked mole rats, bowhead whales, and Greenland sharks share unexpected genetic patterns. We explain how comparative genomics surfaces mRNA candidates.